idera
pharmaceuticals
announces
new
patent
coverage
tilsotolimod
september
exton
globe
newswire
idera
pharmaceuticals
nasdaq
idra
today
announced
patent
trademark
office
issued
patent
patent
allowed
patent
application
application
entitled
immune
modulation
agonists
cancer
treatment
includes
company
investigational
therapy
tilsotolimod
new
patent
allowed
application
include
claims
directed
methods
treating
colorectal
cancer
crc
patent
head
neck
squamous
cell
carcinoma
hnscc
application
intratumoral
administration
tilsotolimod
combination
certain
immune
checkpoint
inhibitor
therapies
including
proteins
new
coverage
expands
protection
first
tilsotolimod
patent
directed
methods
treating
metastatic
melanoma
issued
november
patents
allowed
application
provide
exclusivity
certain
uses
tilsotolimod
september
crc
patent
hnscc
patent
fortify
beyond
melanoma
strategy
tilsotolimod
currently
includes
ongoing
development
via
trial
hnscc
via
collaboration
abbvie
said
vincent
milano
idera
chief
executive
officer
additional
new
intellectual
property
protections
also
demonstrate
commitment
tilsotolimod
furthering
development
potentially
address
unmet
need
patients
living
colorectal
cancer
involves
abnormal
growth
cells
colon
rectum
type
cancer
typically
tested
determine
msi
status
inform
treatment
approach
prognosis
msi
stands
microsatellite
means
high
amount
instability
tumor
whereas
mss
tumors
microsatellite
according
american
cancer
society
references
annually
united
states
approximately
people
diagnosed
crc
mss
approximately
deaths
attributed
crc
shown
highly
immunosuppressive
approved
immunotherapy
options
given
tilsotolimod
mechanism
action
activating
dendritic
cells
may
serve
complementary
function
within
immunosuppressive
tumor
microenvironment
patients
phase
study
evaluate
tilsotolimod
combination
stable
colorectal
cancer
patients
information
trial
please
visit
hnscc
abbvie
collaboration
head
neck
squamous
cell
carcinoma
hnscc
develop
flat
cells
form
lining
mouth
nose
throat
hnscc
metastasizes
parts
body
lymph
nodes
lungs
cancer
worse
prognosis
fatal
hnscc
seventh
common
cancer
worldwide
year
approximately
new
cases
diagnosed
approximately
deaths
attributed
hnscc
united
states
patients
relapsed
metastatic
hnscc
overall
survival
benefit
demonstrated
immune
therapies
versus
standard
care
chemotherapy
challenge
remains
increase
percentage
patients
responding
treatments
currently
ranges
depending
line
therapy
given
tilsotolimod
mechanism
action
activating
dendritic
cells
may
serve
complementary
function
immune
therapies
within
tumor
microenvironment
hnscc
patients
information
regarding
idera
collaboration
abbvie
hnscc
see
idera
september
press
release
visit
tilsotolimod
tilsotolimod
investigational
synthetic
receptor
agonist
intratumoral
injection
tilsotolimod
shown
promote
innate
adaptive
immune
activation
tumors
active
immune
response
appear
respond
better
cpis
exclude
inhibit
immune
cells
tilsotolimod
combination
cpis
may
cause
regression
locally
injected
distant
tumor
lesions
increase
number
patients
benefit
immunotherapy
tilsotolimod
received
fast
track
designation
orphan
drug
designation
fda
evaluated
multiple
tumor
types
combination
multiple
checkpoint
costimulation
therapies
information
tilsotolimod
trials
please
visit
idera
pharmaceuticals
harnessing
approach
earliest
researchers
immunotherapy
company
vast
experience
developing
proprietary
immunology
platforms
idera
development
program
focused
priming
immune
system
play
powerful
role
fighting
cancer
ultimately
increasing
number
people
benefit
immunotherapy
idera
also
continues
focus
acquisition
development
ultimate
commercialization
drug
candidates
oncology
rare
disease
indications
characterized
small
patient
populations
serious
unmet
needs
learn
idera
visit
forward
looking
statements
press
release
contains
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
statements
historical
fact
included
incorporated
press
release
including
statements
regarding
company
strategy
future
operations
collaborations
intellectual
property
cash
resources
financial
position
future
revenues
projected
costs
prospects
clinical
trials
plans
objectives
management
statements
words
believes
anticipates
estimates
plans
expects
intends
may
could
potential
likely
projects
continue
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
idera
guarantee
achieve
plans
intentions
expectations
disclosed
statements
place
undue
reliance
company
statements
several
important
factors
could
cause
idera
actual
results
differ
materially
indicated
implied
statements
factors
may
cause
difference
include
whether
company
cash
resources
sufficient
fund
company
continuing
operations
development
company
programs
period
anticipated
whether
interim
results
clinical
trial
preliminary
results
reported
release
predictive
final
results
trial
whether
results
obtained
preclinical
studies
clinical
trials
results
described
release
indicative
results
generated
future
clinical
trials
including
clinical
trials
different
disease
indications
whether
products
based
idera
technology
advance
clinical
trial
process
anticipated
warrant
submission
regulatory
approval
whether
products
receive
approval
food
drug
administration
equivalent
foreign
regulatory
agencies
whether
company
products
receive
approval
successfully
distributed
marketed
whether
company
collaborations
successful
important
factors
set
forth
caption
risk
factors
company
annual
report
filed
form
period
ended
december
company
quarterly
report
filed
form
period
ended
september
although
idera
may
elect
point
future
company
assume
obligation
update
statements
disclaims
intention
obligation
update
revise
statement
whether
result
new
information
future
events
otherwise
yervoy
ipilimumab
opdivo
nivolumab
registered
trademarks
bristol
myers
squibb
idera
pharmaceuticals
contacts
jill
conwell
investor
relations
corporate
communications
phone
john
kirby
chief
financial
officer
phone
